Info
Apalutamide
- Fewer CNS S/E than enzalutamide. OS benefit vs. ADT alone in high volume (visceral mets & 1+ bone lesion, or 4+ bone lesions, at ↣ least 1 outside axial skeleton) & low-volume metastatic dz (NEJM 2019;381:13; Lancet Oncol 2019;20(11):1518)